Ankrd34B: A Potential Drug Target and Biomarker (G340120)

Target Name: ANKRD34B

NCBI ID: G340120

ANKRD34B

Ankrd34B: A Potential Drug Target and Biomarker

ANKRD34B (AN34B_HUMAN), a protein encoded by the human gene ANKRD34B, is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function and regulation in the human body have been extensively studied, and its potential implications for human health have led to a growing interest in its research and development as a drug.

The ANKRD34B gene is located on chromosome 12q34 and encodes a protein with 255 amino acid residues. The protein is involved in various cellular processes, including cell adhesion, migration, and invasion, and has been implicated in various physiological processes, including cell signaling, cell survival, and cell proliferation.

Initial studies suggested that ANKRD34B is involved in the regulation of cell proliferation and survival, and that its expression is regulated by various factors, including growth factors, apoptosis, and cellular stress. Further research has also shown that ANKRD34B is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Recent studies have also shown that ANKRD34B is involved in the regulation of pain perception and neuroinflammation. Its expression has been observed in various types of cancer, including breast, ovarian, and colorectal cancer, and has been linked to the development and progression of these diseases.

In addition to its involvement in cancer and neurodegenerative diseases, ANKRD34B has also been shown to be involved in the regulation of other physiological processes, including immune response, inflammation, and stress. Its expression has been observed in various types of immune cells, including T cells, B cells, and natural killer cells, and has been linked to the regulation of immune responses and inflammation.

The potential implications of ANKRD34B as a drug target are significant. Its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders, makes it an attractive target for drug development. Additionally, its various functions and roles in cellular processes make it a potential candidate for a variety of drugs, including anti-cancer, anti-neurodegenerative, and anti-inflammatory drugs.

The development of ANKRD34B as a drug target is currently being actively investigated by researchers at various institutions. Initial studies have shown that ANKRD34B can be effectively targeted with small molecules, antibodies, and other therapeutic agents. Further research is needed to determine the most effective and safe method for its targeting and use as a drug.

In conclusion, ANKRD34B (AN34B_HUMAN) is a protein with significant potential as a drug target and biomarker for various diseases. Its various functions and roles in cellular processes make it an attractive target for drug development, and its potential implications for human health are significant. Further research is needed to determine the most effective and safe method for its targeting and use as a drug.

Protein Name: Ankyrin Repeat Domain 34B

The "ANKRD34B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD34B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets